+

WO1993000094A3 - Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine - Google Patents

Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine Download PDF

Info

Publication number
WO1993000094A3
WO1993000094A3 PCT/GB1992/001083 GB9201083W WO9300094A3 WO 1993000094 A3 WO1993000094 A3 WO 1993000094A3 GB 9201083 W GB9201083 W GB 9201083W WO 9300094 A3 WO9300094 A3 WO 9300094A3
Authority
WO
WIPO (PCT)
Prior art keywords
migraine
treatment
portal hypertension
tetrahydrobenzazepine derivatives
tetrahydrobenzazepine
Prior art date
Application number
PCT/GB1992/001083
Other languages
French (fr)
Other versions
WO1993000094A2 (en
Inventor
John Gerard Ward
Rodney Christopher Young
Alberto Julio Kaumann
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919113379A external-priority patent/GB9113379D0/en
Priority claimed from GB919113377A external-priority patent/GB9113377D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to EP92912293A priority Critical patent/EP0589973A1/en
Priority to KR1019930703940A priority patent/KR940701258A/en
Priority to JP4511087A priority patent/JPH06508352A/en
Publication of WO1993000094A2 publication Critical patent/WO1993000094A2/en
Publication of WO1993000094A3 publication Critical patent/WO1993000094A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Tetrahydrobenzazepine derivatives are disclosed as medicaments.
PCT/GB1992/001083 1991-06-21 1992-06-17 Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine WO1993000094A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP92912293A EP0589973A1 (en) 1991-06-21 1992-06-17 Medicaments
KR1019930703940A KR940701258A (en) 1991-06-21 1992-06-17 Use of tetrahydrobenzazine derivatives for the treatment of portal hypertension and migraine headaches
JP4511087A JPH06508352A (en) 1991-06-21 1992-06-17 Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919113379A GB9113379D0 (en) 1991-06-21 1991-06-21 Medicaments
GB9113377.7 1991-06-21
GB9113379.3 1991-06-21
GB919113377A GB9113377D0 (en) 1991-06-21 1991-06-21 Medicaments

Publications (2)

Publication Number Publication Date
WO1993000094A2 WO1993000094A2 (en) 1993-01-07
WO1993000094A3 true WO1993000094A3 (en) 1993-03-04

Family

ID=26299102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/001083 WO1993000094A2 (en) 1991-06-21 1992-06-17 Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine

Country Status (9)

Country Link
EP (1) EP0589973A1 (en)
JP (1) JPH06508352A (en)
KR (1) KR940701258A (en)
AU (1) AU1927992A (en)
CA (1) CA2110575A1 (en)
IE (1) IE921990A1 (en)
MX (1) MX9203012A (en)
PT (1) PT100602A (en)
WO (1) WO1993000094A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US8952197B2 (en) 2009-06-18 2015-02-10 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
EA000769B1 (en) * 1996-03-25 2000-04-24 Эли Лилли Энд Компани Method for treating migraine pain
WO2002074746A1 (en) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
DK1572215T3 (en) 2002-12-20 2010-01-11 Glaxo Group Ltd Benzo [D] azepine derivatives for the treatment of neurological disorders
SI2332921T1 (en) 2003-06-17 2016-06-30 Arena Pharmaceuticals, Inc. 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride
EA016558B1 (en) 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Benzazepine derivatives useful for the treatment of 5htreceptor associated diseases
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
CA2589988C (en) 2004-12-21 2017-02-14 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
AU2005322183B2 (en) 2004-12-23 2012-03-29 Arena Pharmaceuticals, Inc. 5HT2C receptor modulator compositions and methods of use
EP2001852A2 (en) 2006-04-03 2008-12-17 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
ES2522587T3 (en) 2006-12-05 2014-11-17 Arena Pharmaceuticals, Inc. Processes for preparing (R) -8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzacepin and intermediates thereof
CN102015591B (en) 2008-03-04 2014-01-29 艾尼纳制药公司 Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-choro-i-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
KR101913442B1 (en) 2010-09-01 2018-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Modified-release dosage forms of 5-ht2c agonists useful for weight management
MX2013002418A (en) 2010-09-01 2013-08-01 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment.
CN103189358A (en) * 2010-09-01 2013-07-03 艾尼纳制药公司 Fast-dissolve dosage forms of 5-ht2c agonists
KR20130101524A (en) * 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. Non-hygroscopic Salts of 5-HT2C Agonists
EP2611782A1 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
MX2015004532A (en) 2012-10-09 2016-01-20 Arena Pharm Inc Method of weight management.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229510A1 (en) * 1985-12-20 1987-07-22 Smithkline Beecham Corporation Sulfinyl and sulfonyl substituted-3-benzazepines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229510A1 (en) * 1985-12-20 1987-07-22 Smithkline Beecham Corporation Sulfinyl and sulfonyl substituted-3-benzazepines

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Australian and New Zealand Journal of Medicine, vol. 18, no. 3, 1988, J.W. LANCE: "Fifty years of migraine research", pages 311-317, see page 312, column 1 - page 313, column 1; page 316, paragraph 1 *
Australian and New Zealand Journal of Medicine, vol. 19, no. 5, supplement 1, 1989, P.J. GOADSBY et al.: "Preliminary results for the use of GR43175, a new SHT1 receptor agonist, in the treatment of acute migraine", page 615, see the whole document *
British Journal of Pharmacology, vol. 89, no. 3, November 1986, The Gresham Press, (GB), S.A. CUMMINGS et al.: "Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats", pages 501-513, see the whole article *
Cardiovascular Drugs and Therapy, vol. 4, supplement 1, 1990, Kluwer Academic Publishers, (US), D. LEBREC: "Portal hypertension: serotonin and pathogenesis", pages 33-35, see the whole article *
Clin. Physiol. Biochem., vol. 8, supplement 3, 1990, S. Karger AG, (Basel, DE), P.A. VAN ZWIETEN et al.: "Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs", pages 1-18, see page 6, column 1, line 37 - column 2, line 30; page 12, column 1, line 29 - column 2, line 17 *
Drug Development and Industrial Pharmacy, vol. 15, no. 4, 1989, Marcel Dekker, Inc., N. RAJAGOPALAN et al.: "Solubility properties of the serotonergic agonist 2,3,4,5-tetrahydro-8-(methylsulfonyl)-1H-3-benzazepin-7-ol", pages 489-497, see abstract; page 490: "Introduction" *
Gastroenterology, vol. 94, no. 5, part 2, May 1988, 89th Annual Meeting of the American Gastroenterological Association, New Orleans, Louisiana, 14-20 May 1988, H.S. ORMSBEE, III et al.: "SK&F103829 is a selective partial agonist at serotonergic 5-HT2 receptors, evaluation in functional receptor assays", page A336, see the whole abstract *
Hepatology, vol. 9, no. 2, February 1989, American Association for the Study of Liver Diseases, (US), R. MASTAI et al.: "Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension", pages 265-268, see the whole article *
La Revue du Praticien, vol. 40, no. 5, 11 February 1990, (Paris, FR), P.-J. GOADSBY et al.: "Physiopathologie de la migraine", pages 389-393, see page 391, column 1 *
Recenti Progressi in Medicina, vol. 80, no. 12, December 1989, J.W. LANCE: "Headache: classification, mechanism and principles of therapy, with particular reference to migraine", pages 673-680, see page 673: "Summary"; page 676, column 2 - page 677, column 1; page 678, column 2 *
The American Journal of Surgery, vol. 160, no. 1, July 1990, (US), D. LEBREC: "Current status and future goals of the pharmacologic reduction of portal hypertension", pages 19-25, see the whole article *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US8952197B2 (en) 2009-06-18 2015-02-10 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists

Also Published As

Publication number Publication date
CA2110575A1 (en) 1993-01-07
KR940701258A (en) 1994-05-28
IE921990A1 (en) 1992-12-30
JPH06508352A (en) 1994-09-22
MX9203012A (en) 1993-07-01
PT100602A (en) 1993-09-30
AU1927992A (en) 1993-01-25
EP0589973A1 (en) 1994-04-06
WO1993000094A2 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
CA2186260A1 (en) Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide
HUS1400001I1 (en) Quinazoline derivatives, producing them and pharmaceutical compositions containing the compounds
AU3074289A (en) 2,2'-iminobisethanol derivatives as potentiators of the effects of blood pressure reducing agents
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
HUP9802565A3 (en) N-benzyl-dioxothiazolidinylmethyl-benzamide derivatives, pharmaceutical compositions containing them and process for producing the same
HU9503116D0 (en) Oxazolidinedione derivatives, their production and use field of the invention
AU6878894A (en) 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
AU4123793A (en) Benzimidazole derivatives
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
AU7184994A (en) Imidazole derivatives as therapeutic agents
AU2508597A (en) Drug for the treatment of tumours
HUP9602640A3 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
MY110149A (en) Compounds for the treatment of neurodegenerative disorders
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
AU3467697A (en) 3'-oximino-2',3'-dideoxynucleosides and derivatives of the same
IL109059A0 (en) Pharmaceutical compositions for the treatment of post-operative nausea and vomiting
GR3024654T3 (en) Benzofuranone and benzodifurantrione derivatives and process for the preparation of benzodifuranones.
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU3347493A (en) Pharmaceutically active substituted benzimidazole derivatives
AU5014396A (en) Diazabicyclo{3.3.1}nonane derivatives and intermediates ther eof, medicinal use of the same, and processes for producing the same
AU4845196A (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
AU1251295A (en) Substituted benzimidazole, processes for its preparation and its pharmaceutical use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: 2110575

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992912293

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992912293

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992912293

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载